Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy

In the era of precision medicine, the impact of personalized dosing of busulfan is not clear. We undertook a retrospective analysis of 78 patients with myeloid malignancies who received fludarabine and busulfan (FluBu4) with or without measuring Bu pharmacokinetics (Bu PK) and those who received bus...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Adv Hematol
Hlavní autoři: Farhan, Shatha, Bazydlo, Michael, Neme, Klodiana, Mikulandric, Nancy, Peres, Edward, Janakiraman, Nalini
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698787/
https://ncbi.nlm.nih.gov/pubmed/29250116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/8690416
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky